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Intestinal tumors in ApcMin/+ mice are suppressed by over-production of HPGDS, which is a
glutathione transferase that forms prostaglandin D2 (PGD2). We characterized naturally occurring
HPGDS isoenzymes, to see if HPGDS variation is associated with human colorectal cancer risk.
We used DNA heteroduplex analysis and sequencing to identify HPGDS variants among healthy
individuals. HPGDS isoenzymes were produced in bacteria, and their catalytic activities were
tested. To determine in vivo effects, we conducted pooled case-control analyses to assess whether
there is an association of the isoenzyme with colorectal cancer. Roughly 8% of African Americans
and 2% of Caucasians had a highly stable Val187lle isoenzyme (with isoleucine instead of valine
at position 187). At 37 °C, the wild-type enzyme lost 15% of its activity in one hour, whereas the
Val187Ile form remained >95% active. At 50 °C, the half life of native HPGDS was 9 minutes,
compared to 42 minutes for Val187Ile. The odds ratio for colorectal cancer among African
Americans with Val187Ile was 1.10 (95% CI, 0.75–1.62; 533 cases, 795 controls). Thus, the
Val187Ile HPGDS isoenzyme common among African Americans is not associated with
colorectal cancer risk. Other approaches will be needed to establish a role for HPGDS in
occurrence of human intestinal tumors, as indicated by a mouse model.
Keywords
glutathione transferase; HPGDS; prostaglandin D2; colon cancer
1. Introduction
D series prostaglandins were discovered 40 years ago [1], and prostaglandin D2 (PGD2) has
since proven to be a mediator of sleep [2, 3], platelet aggregation, inflammation, smooth
muscle contraction, and allergic asthma [4]. Hematopoietic prostaglandin D synthase
(HPGDS; NCBI Gene ID 27306) converts PGH2 to PGD2, and the enzyme is also a σ class
glutathione transferase [5, 6]. HPGDS was originally found in the rat spleen [7–11] and later
in other tissues [12, 13]. The 3-dimensional structure of HPGDS has been defined for
possible drug targeting, due to involvement of HPGDS in allergic asthma and inflammation
[14].
Tumor-prone ApcMin/+ mice deficient in HPGDS developed 50% more intestinal adenomas
compared to controls. Conversely, ApcMin/+ mice that over-produced the enzyme from
HPGDS transgenes had 70% fewer tumors [15]. The concept of PGD2 as a tumor
suppressing molecule is supported by faster growth of Lewis lung cancer cells implanted
onto mice that lack PTGDR [16]. Here we describe a high stability, Val187Ile HPGDS
isoenzyme among African Americans and assess its impact on colorectal tumors.
2. Materials and methods
2.1 Identification of gene variants [17]
We used blood specimens from the UCLA Tissue Typing Laboratory to identify common
HPGDS variants. One mm squares of dried blood on blotter paper served as PCR templates
(903 paper; Whatman GE Healthcare; Piscataway, NJ). We used DNA heteroduplex analysis
to screen for variants in exons and flanking intron regions in 47 African American and 47
white subjects. DNA sequencing identified the base substitutions. Last, we used allele-
specific PCR to search for these substitutions in other ethnic groups [Chinese (Hong Kong),
Filipino, Hispanic, Indian (Asian), Japanese, Korean, and Samoan). PCR primers are shown
in Table S1.
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2.2 HPGDS expression vectors and mutagenesis
We prepared a human HPGDS coding fragment by use of PCR, with human spleen cDNA
as the template (Clontech; Mountain View, CA). PCR primers were: 5’-TAT ACA TAT
GCC AAA CTA CAA ACT CAC T-3’ (HPGDS-L14B) and 5’-TAT AGG ATC CCT AGA
GTT TGG TTT GGG G-3’ (HPGDS-R12). Primer L14B contained an NdeI restriction site
(CATATG) and a total of 21 nucleotides of the HPGDS sequence, beginning with the ATG
start site. Primer R12 contained 18 nucleotides of HPGDS (up to and including the TAG
stop codon), followed by a BamHI site (GGA TCC). We subcloned the PCR product
between NdeI and BamHI restriction sites in a bacterial plasmid (pET-5a; Novagen EMD
Biosciences, Inc.; San Diego, CA), introduced selected mutations (QuikChange site-directed
mutagenesis; Stratagene; La Jolla, CA), and checked the final plasmids by sequencing.
Mutagenic oligonucleotides were: 5'-GGA ACA ATG TCA TGT TGA TGC TGT TGT
GGA CAC TCT GG-3’ and 5’-CCA GAG TGT CCA CAA CAG CAT CAA CAT GAC
ATT GTT CC-3’ (for Ile91Val); 5’-GCT CAC GTA TAA TGC GCC TCA TCT TAC GCA
AGA CTT GG-3’ and 5’-CCA AGT CTT GCG TAA GAT GAG GCG CAT TAT ACG
TGA GC-3’ (for Met128Thr); 5’-CCA AGC CAT TCC TGC CAT CGC TAA CTG GAT
AAA ACG-3’ and 5’-CGT TTT ATC CAG TTA GCG ATG GCA GGA ATG GCT TGG-3’
(for Val187Ile).
2.3 Biochemical characterization of HPGDS isoenzymes
HPGDS isoenzymes were produced in E. coli strain BL21 (DE3; Stratagene). Cells were
grown in L-broth with ampicillin to an absorbance of 0.7 at 600 nm and then induced with
IPTG. Cells were suspended in phosphate buffered saline (PBS) with 5 mM dithiothreitol
(DTT) and lysed with lysozyme (0.5 mg/ml) while stirring for 30 minutes at 4 °C. We
recovered soluble proteins by centrifugation (12,000 rpm in a GSA rotor at 4 °C).
Ammonium sulfate was added to a concentration of 60% saturation. Pellets were
resuspended in PBS with 5 mM DTT and 5 mM MgCl2 (buffer 2) and then loaded onto a
Sephadex G-75 column (GE Healthcare). Peak fractions containing HPGDS were pooled
and loaded onto a glutathione-agarose column (Sigma-Aldrich; St. Louis, MO), washed with
3 column volumes of buffer 2, and eluted with 2 column volumes of fresh 50 mM Tris-Cl
pH 9.0 with 10 mM reduced glutathione. Peak fractions were dialyzed into 50 mM NaPO4
(pH 7.0) containing 10% glycerol at 4 °C, aliquoted, and stored at −80 °C.
We measured glutathione transferase activity of HPGDS enzymes with 1-chloro-2,4-
dinitrobenzene (CDNB) as substrate [18]. PGD2 synthesizing activity was measured with
[1-14C]PGH2 as substrate [19].
2.4 Modeling of the 3-dimensional structure of the HPGDS Val187Ile variant
Molecular modeling of the variant enzyme was based on the crystal structure of native,
Mg2+-bound HPGDS at 1.8 Å resolution (PDB entries 1IYI and IIYH; [14, 20]). We used
the software package, ‘O,’ to select the most stable rotamer of residue Ile187 [21]. CNS
programs [20] were used to obtain an energy-minimized model of the mutant enzyme,
without unfavorable contacts associated with the Cδ atom of Ile187.
2.5 Epidemiologic studies of colorectal neoplasia
We used data on African Americans in 6 published case-control studies in analyses of the
HPGDS Val187Ile variant. For adenomas, we used the University of Southern California/
Kaiser sigmoidoscopy study [USC/Kaiser; 22] and the University of North Carolina Diet
and Health Study III [UNC DHS III; 23]. For cancer, we used the Multiethnic Cohort Study
[MECS; 24], the Women’s Health Initiative observational study [WHI; 25], and the North
Carolina Colorectal Cancer Study 1 [NCCCS1; 26, 27] and Study 2 [NCCCS2; 28]. For the
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WHI subjects, we matched the available African American colorectal cancer cases (50) to 3
controls each (from among a total of 6,534 controls), according to baseline age and follow-
up time.
Dried blood spots on blotter paper or DNA samples in solution were tested for Val187Ile, by
use of allele-specific PCR. Samples from USC/Kaiser, UNC DHS III, MECS, and WHI
were tested in duplicate and then re-tested, if initial results were unclear. Samples from
NCCCS1 and NCCCS2 had an initial test and then re-testing, if the initial result was unclear
or to confirm presence of the Val187Ile variant. A randomly chosen quality control subset
(10% of NCCCS1) showed 100% consistency with assigned genotypes.
Additionally, we analyzed a variant of prostaglandin-endoperoxide synthase 2 (PTGS2) --
an enzyme that precedes HPGDS in PGD2 biosynthesis. We used the 4 cancer studies listed
above and a genetic epidemiology study of colorectal cancer in Baltimore [29].
To quantify the heterogeneity between studies, we used Cochran's Q parameter and the
associated P-value, by the use of Stata 10 (StataCorp LP, College Station, TX). Odds ratios
(ORs) and 95% confidence intervals (CIs) were calculated by unconditional logistic
regression, comparing Val187Ile carriers to wild-type subjects (Val/Val) for HPGDS
analyses and Val511Ala carriers to wild-type subjects (Val/Val) for PTGS2 analyses (SAS
version 9.1; SAS Institute; Carey, NC). We adjusted ORs for age (within 5-year intervals)
and gender in the individual studies (except WHI) and for age, gender, and study site in
combined analyses. Variables were retained in logistic regression models if omitting them
changed the OR estimate by at least 10%. Adjustment for body mass index gave the same
results as those without adjustment. Therefore, we omitted body mass index from the
analyses. All P-values were 2-sided, and values <0.05 were considered statistically
significant.
3.0 Results and discussion
3.1 HPGDS variants (Table 1)
Six DNA variants were identified, and 3 of them changed the amino acid sequence:
Ile91Val, Met128Thr, and Val187Ile (reported in [6]). One substitution in the coding region
did not change an amino acid (c.597 C>G), and there were 2 intron variants (IVS2+11 A>C,
IVS3+13 T>C [30]). Variants that changed the amino acid sequence were evaluated further.
Val187Ile allele frequencies were 0.044 among healthy African Americans (106/2,386) and
0.010 among healthy whites (3/294; Table 1). Val187Ile was not detected among small
samples of Chinese (Hong Kong), Hispanics, Asian Indians, Japanese, Koreans (25
individuals each), or Samoans (24 individuals). Three white specimens (from the UCLA
Tissue Typing Laboratory), 2 African American specimens (from the North Carolina DHS
III study), and one Filipino specimen (out of 25 from the UCLA Tissue Typing Laboratory)
had all 3 substitutions (Ile91Val, Met128Thr, and Val187Ile), indicating an allele with at
least 2 of the nucleotide changes.
3.2 Stabilities of HPGDS isoenzymes
We observed weak affinity of human HPGDS for glutathione agarose during purification [6,
31], leading to low recovery of enzymes from E. coli despite high expression from plasmid
vectors. However, we obtained adequate amounts of purified enzymes by increasing the
amounts of MgCl2 and DTT in the binding buffer.
Glutathione transferase specific activities at room temperature were: wild-type, 5.8 ± 0.2;
Val187Ile, 4.7 ± 0.5; Ile91Val, 4.2 ± 0.1; Met128Thr, 3.0 ± 0.1 µmol/min/mg of protein
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(mean ± standard error; 3 determinations). Prostaglandin D synthase specific activities
followed the same order: wild-type, 17.3; Val187Ile, 20.4; Ile91Val, 18.6; Met128Thr, 10.5
µmol/min/mg of protein (single measurements with radio-labeled PGH2 at 37 °C).
Met128Thr converts a hydrophobic thioether side chain to a hydrophilic side chain. The
change occurs between 2 conserved residues in a hydrophobic cavity at the dimer interface
(Leu127, Asp130) [5, 6].
Thermal stabilities of HPGDS variants were first evaluated by use of glutathione transferase
assays. The half-life of the Val187Ile variant increased >4-fold to 42 minutes at 50 °C,
compared to 9 minutes for the wild-type (Fig. 1A). High stability was found with 3
independent enzyme preparations of the wild type and Val187Ile variant and thus was not
due to purification differences.
Similarly, Val187Ile had higher stability when PGD2 synthesis activity was measured.
Specifically, at 50 °C, the half-life for wild-type PGD2 synthesis activity was 14 minutes,
whereas the Val187Ile variant retained 95% of its activity over this interval (Fig. 1B). In
contrast, the Ile91Val and Met128Thr variants lost half of their activities by 6 minutes at 50
°C (Fig. 1B). At 37 °C, the wild-type enzyme lost 15% of its activity in one hour, whereas
Val187Ile remained >95% active (Fig. 1C). The Val187Ile allele was in the HPGDS clone
expressed by Jowsey et al. [6], but enzyme stability was not reported.
3.3 3-Dimensional structure of the Val187Ile isoenzyme
Residue 187 lies in the N-terminal portion of helix-9, far from the catalytic and dimerization
domains of the enzyme. In native HPGDS, helix-9 and its adjoining C-terminal loop are held
in place by one van der Waals and 7 hydrogen bonding interactions. However, there are 3
more van der Waals interactions in the variant enzyme (Figs. 1D–E). These interactions are
likely to reduce mobility of helix-9 and of the outer regions of the enzyme.
3.4 Case-control analyses of the HPGDS Val187Ile variant and colorectal tumors
Highly expressed transgenic HPGDS enzymes inhibit intestinal adenomas in ApcMin/+ mice
[15]. Therefore, we did case-control analyses to see if the highly stable HPGDS isoenzyme
prevents colorectal tumors in humans. As described in section 2.5, we used DNA and data
from 6 published studies of colorectal tumors. Subjects in these studies were characterized
by age, gender, body mass index, and NSAID usage (Table S2).
The OR for colorectal cancer with the Val187Ile variant (versus wild-type Val/Val) was
1.10 (95% CI, 0.75–1.62; 533 cases and 795 controls). Similarly, the OR for colorectal
adenomas was 0.93 (95% CI, 0.46–1.86; 161 cases and 219 controls). Thus, there was no
change in risk for colorectal tumors with Val187Ile (Table 2).
Strengths of the analyses were population-based cases and controls in the Multiethnic
Cohort, North Carolina, and WHI studies. The USC/Kaiser sigmoidoscopy-based study
screened asymptomatic individuals for a first diagnosis of adenomas, but 15–20% of
individuals with no polyp by sigmoidoscopy may have adenomas more proximally [32]. A
limitation was low prevalence of Val187Ile. Specifically, the combined colorectal cancer
studies had 80% power to detect an OR of ~0.5. Larger samples are needed to exclude
weaker associations.
We also measured excretion of 11,15-dioxo-9α-hydroxy-2, 3, 4, 5-tetranorprostan-1,20-
dioic acid (tetranor PGDM) in relation to Val187Ile in a pilot study of healthy African
American volunteers. Tetranor PGDM is the most abundant urinary metabolite of PGD2
[33]. Median values of urinary tetranor PGDM (in ng/mg of creatinine) were 5.16 for
controls (18 individuals; mean age, 35.4 years) and 6.68 for Val187Ile carriers (5
Tippin et al. Page 5













individuals; mean age, 39.2). The results indicate no difference in tetranor PGDM excretion
for Val187Ile carriers and controls (P = 0.48, Mann-Whitney; data not shown). However, the
study was limited by difficulties in recruiting non-smokers (i.e., subjects with undetectable
urine cotinine). Smoking induces PTGS2 [34], which in turn produces PGH2 (the substrate
for HPGDS) -- thereby potentially raising PGD2 metabolite levels. Larger studies are needed
for a definitive interpretation.
3.5 Case-control analyses of the PTGS2 Val511Ala variant
We considered whether variants of phospholipase A2 (group IVA; PLA2G4A) and PTGS2
-- 2 enzymes that precede HPGDS in PGD2 biosynthesis -- might influence HPGDS effects.
We found no DNA variant that changes the PLA2G4A amino acid sequence among 45
blood specimens from healthy African Americans (Table S3).
For PTGS2, Fritsche et al. [35] reported a variant -- alanine replacing valine at residue 511
-- that has the potential to alter the cyclooxygenase active site (Fig. S1; rs5273; [17]).
Enzyme assays showed no differences in catalytic function of the Val511Ala variant, when
measured with arachidonic acid, linoleic acid, or 2-arachidonyl glycerol as substrates.
However, PTGSs can also convert various endogenous or dietary fatty acids to different
prostanoid products [36], such as series 1 and 3 prostaglandins. Moreover, PTGS2 that has
been acetylated by aspirin converts arachidonic acid into 15-epi-lipoxin, rather than PGH2
[37]. Several mutations in the cyclooxygenase active site of PTGSs can also result in
production of non-prostanoid compounds [38].
The Val511Ala PTGS2 isoenzyme occurs among 8–10% of African Americans. There were
(non-statistically significant) inverse associations for colon cancer or adenomas among
individuals who were Val511Ala carriers and/or users of nonsteroidal anti-inflammatory
drugs (NSAIDs) [17, 26].
Therefore, we produced new data from WHI and NCCCS2 subjects and combined them
with all published data in Tables S4 and S5 [17, 26, 29]. However, we found no association
with colorectal cancer in relation to the PTGS2 variant (Val511Ala carriers versus wild-type
Val/Val subjects; overall OR, 0.77; 95% CI, 0.52–1.13; 704 cases and 1,038 controls; Table
S5A).
We also analyzed Val511Ala apart from NSAID usage and in combination with NSAID use,
in order to assess for interaction between Val511Ala and NSAIDs. Among all subjects, the
OR for colorectal cancer among NSAID users was 0.80 (95% CI, 0.63–1.01; Table S5B),
indicating no preventive effect in this study population. Results were similar when
individuals with Val511Ala were excluded (OR, 0.85; 95% CI, 0.66–1.09; Table S5B).
Among NSAID non-users, the OR for subjects with Val511Ala versus wild-type subjects
was 0.95 (95% CI, 0.57–1.57; Table S5C), indicating no effect of Val511Ala apart from
NSAID use. Finally, compared to wild-type individuals who were non-users, the OR was
0.41 (95% CI, 0.18–0.92; Table S5D) for individuals who had Val511Ala and were users.
However, numbers of subjects in this group were small (8 cases and 27 controls), and there
was no statistical interaction between NSAID use and Val511Ala (P = 0.17).
These analyses show no association between Val511Ala and risk for colorectal cancer.
Strengths of the analyses include the high quality of subject ascertainment and data
collection, including 3 population-based studies. However, more subjects are needed to
exclude low level associations. The pooled data had 80% power to detect an OR for cancer
of ~0.5. Other limitations were lack of NSAID data for 20% of individuals (119 cases; 222
controls) and varying definitions of NSAID use.
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We also evaluated prostaglandin production in relation to Val511Ala among healthy African
Americans and found no change in PGE2 production (by peripheral blood monocytes) or
excretion of PGE-M and PGI-M by 4 healthy Val511Ala carriers (not shown) [39]. Taken
together, the data support an interpretation that the PTGS2 Val511Ala variant is not
phenotypically important.
3.6 Comparison of the Val187Ile variant to HPGDS transgenes and knockouts in mice
As mentioned in the introduction, ApcMin/+ mice with human HPGDS transgenes had 70%
fewer intestinal adenomas. In these mice, the human HPGDS transgene (driven by a strong
constitutive promoter) produced 375 times more mRNA transcripts than were found for the
endogenous mouse Hpgds genes [15]. Conversely, ApcMin/+ mice with heterozygous or
homozygous Hpgds gene knockouts had 50% more tumors compared to controls. These
mice should produce at least 50% less HPGDS in expressing cells.
In contrast to these mutations introduced in mice, the Val187Ile variant should mainly affect
removal of HPGDS, rather than production. Historically, rates of heat inactivation of
enzymes in vitro correlated roughly with enzyme half-lives in vivo [40]. A 15% loss of
wild-type HPGDS activity in one hour at 37 °C (Fig. 1C) corresponds to a half-life for
unfolding of 4.3 hours. The half-life for unfolding of the Val187Ile enzyme at 37 °C may
then be 20 hours, as estimated from comparison of the half-lives at 50 °C (42 minutes for
Val187Ile versus 9 minutes for wild-type HPGDS; Fig. 1A).
During the first half-life after HPGDS production in cells that are heterozygous for
Val187Ile, the average ratio of the level of the Val187Ile isoenzyme to the level of wild-type
HPGDS may be only 1.3 to 1, as estimated from half-lives for unfolding and exponential
decay. This ratio corresponds to only a 1.15-fold increase in the HPGDS level [or (1 + 1.3)/
2]. Thus, the amount of lingering HPGDS is expected to be much less than produced from a
375-fold overexpressed HPGDS transgene in mice.
Degradation of intracellular proteins can also be regulated by the ubiquitin/proteasome
system [41, 42]. For example, PTGS2 is removed by the ubiquitin system and has a half-life
of 3.5 to 8 hours in colon cancer cells [43]. A 19-amino acid segment located 6 residues
from the C-terminus targets PTGS2 for proteasomal degradation [44]. On the other hand,
PTGS1 is constitutively produced in many tissues and has a long half-life (>12 hours).
(PTGS1 is the major source of PGH2 for PGD2 production under normal conditions [33].)
However, there are no data on ubiquitin and HPGDS.
It seems likely that the lack of a tumor suppressing effect of the Val187Ile isoenzyme may
be due to inadequate amounts of HPGDS, compared to amounts found in HPGDS transgenic
mice. Thus, results of our case-control studies on Val187Ile are compatible with an
interpretation that high levels of PGD2 may be needed to suppress intestinal tumors,
assuming that the mouse results represent PGD2 effects in humans. However, because our
data can only exclude protective effects with ORs < 0.5 (section 3.5), low statistical power
may also be a reason for lack of a detectable effect of the variant.
3.7 Other approaches to studies of PGD2 and colorectal cancer
Other bioactive molecules that influence PGD2 effects include prostaglandin catabolizing
enzymes and PGD2 receptors. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is
recognized as a major enzyme for prostaglandin degradation, but PGD2 is a poor substrate
for the enzyme [45]. Alternatively, the PGD2 receptor, PTGDR (also known as DP1; Gene
ID 5729) appears to be involved in growth of intestinal tumors. For example, Gustaffson et
al. found 5-fold lower expression of PTGDR in colorectal cancers, compared to normal
tissues (62 tumors and 43 normal tissues, from 62 patients [46]). Galamb et al. observed
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decreasing PTGDR expression going from normal tissues, to adenomas, to early cancers
(Dukes A, B), and to advanced cancers (Dukes C, D; [47]).
Several PTGDR variants have been cataloged, including nonsense mutations (W48X and
Y177X [48]). Screening for PTGDR nonsense variants may be a potential way to analyze
colorectal cancer in relation to PGD2 effects by a genetic epidemiology approach. However,
frequencies of the currently known nonsense alleles are very low.
4.0 Conclusions
A highly stable Val187Ile HPGDS variant occurs in 8% of African Americans. There was
no protective effect of the variant found against colorectal cancer. Inhibition of intestinal
tumors by transgenic HPGDS in ApcMin/+ mice was associated with 375-fold over-
expression of HPGDS [15], which most likely produces more HPGDS than is found with
Val187Ile. Therefore, although the naturally occurring Val187Ile isoenzyme differs
biochemically from the wild-type enzyme and is fairly common among African Americans,
other studies will be needed to establish a role for PGD2 in development of intestinal tumors
in humans, as predicted from mouse models. Analysis of PGD2 receptor (PTGDR) variants
may be another approach.
Highlights
> We conducted a systematic survey of naturally occurring HPGDS enzyme variants. >
A high stability Val187Ile variant occurs in 8% of African Americans and 2% of
Caucasians. > Val187Ile does not protect against colon cancer. > Other methods will be
needed to establish a role for HPGDS in development of human intestinal tumors, as
shown by mouse model data.
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(A, B, C) Thermal stabilities of HPGDS isoenzymes. Enzymes were pre-incubated for the
indicated times, followed by activity assays. Initial activities were set to 100%. Symbols: ●,
wild-type; ■, Ile91Val; ▲, Met128Thr; ▼, Val187Ile. (A) Glutathione transferase (GST)
activities at 50 °C with 1-chloro-2,4-dinitrobenzene (3 independent assays). Half-lives
(minutes) were: wild-type, 8.6 ± 0.1; Ile91Val, 4.3 ± 1.9; Met128Thr, 2.0 ± 0.5; Val187Ile,
41.7 ± 9.3 (P < 0.05, ANOVA with Dunnett’s method). (B) PGD2 synthesis activities at 50
°C with radiolabeled PGH2. (C) PGD2 synthesis activities at 37 °C, as in B. (D, E) Structure
of the Val187Ile isoenzyme, based on the crystal structure of native, Mg2+-bound HPGDS at
1.8 Å resolution [PDB entries 1IYI and IIYH]. (D) Ribbon drawing of dimeric HPGDS. The
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Ile187 side chain is a red stick figure in helix-9. (E) Stereo views of the region near Ile187.
Added van der Waals interactions occur between the Cδ atom of Ile 187 and the O (Tyr 20,
3.73 Å), Cβ (Tyr 24, 3.73 Å) and Cς (Phe 151, 3.69 Å) atoms of nearby side chains (red
dotted lines). Interaction between Ile 187 and Phe 151 is predicted to give extra stability to
helix-9.
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